CVI occurs as the result of malfunctioning valves and can lead to varicose veins. Venclose’s CVI treatment uses radio frequency (RF) ablation technology, with its catheters potentially reducing post-operative pain and bruising compared to alternative laser treatment therapy.
The Venclose system has a compact design with two heating length sizes (2.5 cm and 10 cm) in one 6 FR-sized catheter. The design, according to BD, enables physicians to effectively ablate more vein during each heating cycle through its increased heating length compared to competitive RF ablation catheters.
Dual-heating allows physicians to ablate both long and short vein segments with the same catheter, reducing inventory management burden compared to catheters with shorter and/or static heating length sizes. The system also has a touchscreen display and audible tones for thermal delivery to improve the patient and physician experience.
Venclose’s system is currently available in various healthcare settings across the U.S. and areas of Europe, Franklin Lakes, New Jersey-based BD said.
Financial terms for the transaction were not disclosed. BD expects the acquisition to be immaterial to its fiscal 2022 earnings results.
“We’re committed to setting a new standard of excellence for people living with venous disease, and that starts with providing physicians with innovative technologies,” BD Worldwide President of Peripheral Intervention Paddy O’Brien said in the release. “Our acquisition of Venclose will enable us to offer a more robust portfolio of solutions to physicians who are treating the full range of venous conditions.
“The Venclose RF ablation system strategically complements our category-leading portfolio of venous disease technologies and aligns with our focus on innovations that provide transformative solutions to improve outcomes for chronic disease and enable the transition into new care settings.”